What is Nautilus Biotechnology's operating income?

Nautilus Biotechnology's total operating income in 2025 was -$66.84 million, based on the following breakdown: Total Gross Profit: $0.00 Total Operating Expenses: $66.84 million

Nautilus Biotechnology (NAUT) Financials

$1.73 -0.11 (-5.98%)

Closing price 04:00 PM Eastern

Extended Trading

$1.80 +0.08 (+4.34%)

As of 06:42 PM Eastern

Compare

Annual Income Statements for Nautilus Biotechnology

This table shows Nautilus Biotechnology's income and expenses over time, based on annual financial data. All values are USD millions unless otherwise specified.

Metric	2020	2021	2022	2023	2024	2025
Period end date	12/31/2020	12/31/2021	12/31/2022	12/31/2023	12/31/2024	12/31/2025
Net Income / (Loss) Attributable to Common Shareholders	-16	-50	-58	-64	-71	-59
Consolidated Net Income / (Loss)	-16	-50	-58	-64	-71	-59
Net Income / (Loss) Continuing Operations	-16	-50	-58	-64	-71	-59
Total Pre-Tax Income	-16	-50	-58	-64	-71	-59
Total Operating Income	-16	-50	-64	-76	-81	-67
Total Gross Profit	0.00	0.00	0.00	0.00	0.00	0.00
Total Revenue	0.00	0.00	0.00	0.00	0.00	0.00
Total Cost of Revenue	0.00	0.00	0.00	0.00	0.00	0.00
Total Operating Expenses	16	50	64	76	81	67
Selling, General & Admin Expense	3.31	21	26	29	31	26
Research & Development Expense	12	29	38	47	50	41
Total Other Income / (Expense), net	0.00	0.18	5.69	12	11	7.84
Interest & Investment Income	-	0.33	5.82	13	11	7.87
Other Income / (Expense), net	-	-0.15	-0.12	-0.07	-0.08	-0.03
Basic Earnings per Share	($0.54)	($0.60)	($0.46)	($0.51)	($0.56)	($0.47)
Weighted Average Basic Shares Outstanding	29.09M	84.46M	124.59M	124.92M	125.43M	126.26M
Diluted Earnings per Share	($0.54)	($0.60)	($0.46)	($0.51)	($0.56)	($0.47)
Weighted Average Diluted Shares Outstanding	29.09M	84.46M	124.59M	124.92M	125.43M	126.26M
Weighted Average Basic & Diluted Shares Outstanding	-	124.43M	124.87M	125.10M	126.15M	126.56M

This table shows Nautilus Biotechnology's income and expenses over time, based on quarterly financial data. All values are USD millions unless otherwise specified.

Metric	Q3 2023	Q4 2023	Q1 2024	Q2 2024	Q3 2024	Q4 2024	Q1 2025	Q2 2025	Q1 2026
Period end date	9/30/2023	12/31/2023	3/31/2024	6/30/2024	9/30/2024	12/31/2024	3/31/2025	6/30/2025	3/31/2026
Net Income / (Loss) Attributable to Common Shareholders	-16	-17	-19	-18	-16	-18	-17	-15	-15
Consolidated Net Income / (Loss)	-16	-17	-19	-18	-16	-18	-17	-15	-15
Net Income / (Loss) Continuing Operations	-16	-17	-19	-18	-16	-18	-17	-15	-15
Total Pre-Tax Income	-16	-17	-19	-18	-16	-18	-17	-15	-15
Total Operating Income	-19	-20	-22	-21	-19	-20	-19	-17	-16
Total Gross Profit	0.00	-	0.00	0.00	0.00	-	0.00	0.00	0.00
Total Revenue	0.00	-	0.00	0.00	0.00	-	0.00	0.00	0.00
Total Cost of Revenue	0.00	-	0.00	0.00	0.00	-	0.00	0.00	0.00
Total Operating Expenses	19	20	22	21	19	20	19	17	16
Selling, General & Admin Expense	7.08	7.54	8.68	8.35	6.81	7.16	7.31	6.70	6.42
Research & Development Expense	12	12	13	12	12	13	12	10	9.71
Total Other Income / (Expense), net	3.20	2.98	2.88	2.78	2.65	2.39	2.23	2.06	1.43
Interest & Investment Income	3.20	3.03	2.88	2.80	2.67	2.43	2.23	2.08	1.44
Other Income / (Expense), net	0.00	-0.06	-	-0.02	-0.02	-0.05	0.00	-0.02	-0.02
Basic Earnings per Share	($0.13)	($0.13)	($0.15)	($0.14)	($0.13)	($0.14)	($0.13)	($0.12)	($0.12)
Weighted Average Basic Shares Outstanding	124.93M	124.92M	125.14M	125.32M	125.45M	125.43M	126.14M	126.20M	126.63M
Diluted Earnings per Share	($0.13)	($0.13)	($0.15)	($0.14)	($0.13)	($0.14)	($0.13)	($0.12)	($0.12)
Weighted Average Diluted Shares Outstanding	124.93M	124.92M	125.14M	125.32M	125.45M	125.43M	126.14M	126.20M	126.63M
Weighted Average Basic & Diluted Shares Outstanding	124.95M	125.10M	125.27M	125.41M	125.56M	126.15M	126.15M	126.31M	127.08M

This table details how cash moves in and out of Nautilus Biotechnology's business through operations, investing, and financing, using annual figures. All values are USD millions unless otherwise specified.

Metric	2020	2021	2022	2023	2024	2025
Period end date	12/31/2020	12/31/2021	12/31/2022	12/31/2023	12/31/2024	12/31/2025
Net Change in Cash & Equivalents	37	149	-71	-95	8.25	-15
Net Cash From Operating Activities	-14	-39	-46	-52	-59	-51
Net Cash From Continuing Operating Activities	-14	-39	-46	-52	-59	-51
Net Income / (Loss) Continuing Operations	-16	-50	-58	-64	-71	-59
Consolidated Net Income / (Loss)	-16	-50	-58	-64	-71	-59
Depreciation Expense	0.71	1.02	1.22	1.85	2.06	1.75
Amortization Expense	1.92	2.01	1.31	1.20	1.57	3.29
Non-Cash Adjustments To Reconcile Net Income	0.38	8.07	10	12	13	6.84
Changes in Operating Assets and Liabilities, net	-1.39	-0.02	-0.79	-3.22	-5.46	-3.58
Net Cash From Investing Activities	-25	-139	-26	-44	66	35
Net Cash From Continuing Investing Activities	-25	-139	-26	-44	66	35
Purchase of Property, Plant & Equipment	-0.92	-2.27	-2.32	-2.44	-2.12	-1.28
Acquisitions	-	-	-	0.00	-0.76	0.00
Purchase of Investments	-68	-222	-187	-113	-86	-72
Sale and/or Maturity of Investments	44	85	163	72	155	109
Net Cash From Financing Activities	76	327	0.56	0.37	1.14	0.21
Net Cash From Continuing Financing Activities	76	327	0.56	0.37	1.14	0.21
Issuance of Common Equity	-	0.00	0.23	0.26	0.52	0.16
Other Financing Activities, net	0.04	336	0.33	0.10	0.62	0.06

This table details how cash moves in and out of Nautilus Biotechnology's business through operations, investing, and financing, using quarterly figures. All values are USD millions unless otherwise specified.

Metric	Q3 2023	Q4 2023	Q1 2024	Q2 2024	Q3 2024	Q4 2024	Q1 2025	Q2 2025	Q1 2026
Period end date	9/30/2023	12/31/2023	3/31/2024	6/30/2024	9/30/2024	12/31/2024	3/31/2025	6/30/2025	3/31/2026
Net Change in Cash & Equivalents	1.35	-55	6.33	-0.84	-20	23	5.59	1.22	2.24
Net Cash From Operating Activities	-12	-14	-16	-15	-13	-14	-14	-13	-13
Net Cash From Continuing Operating Activities	-12	-14	-16	-15	-13	-14	-14	-13	-13
Net Income / (Loss) Continuing Operations	-16	-17	-19	-18	-16	-18	-17	-15	-15
Consolidated Net Income / (Loss)	-16	-17	-19	-18	-16	-18	-17	-15	-15
Depreciation Expense	0.47	0.56	0.52	0.51	0.52	0.43	0.47	0.46	0.33
Amortization Expense	0.39	0.42	0.32	-1.78	0.37	0.49	0.62	0.74	1.07
Non-Cash Adjustments To Reconcile Net Income	3.11	3.07	3.11	5.44	3.18	3.97	2.17	1.71	1.36
Changes in Operating Assets and Liabilities, net	0.18	-0.92	-1.49	-1.62	-0.74	-1.61	-0.58	-1.22	-1.17
Net Cash From Investing Activities	13	-41	22	14	-7.50	37	20	14	14
Net Cash From Continuing Investing Activities	13	-41	22	14	-7.50	37	20	14	14
Purchase of Property, Plant & Equipment	-0.87	-0.41	-0.65	-0.51	-0.71	-0.25	-0.22	-0.40	-0.51
Purchase of Investments	-5.05	-61	0.00	-16	-44	-27	-6.90	-4.38	-11
Sale and/or Maturity of Investments	19	20	23	31	37	65	27	19	26
Net Cash From Financing Activities	0.02	0.25	0.25	0.32	0.14	0.44	0.02	0.10	1.11
Net Cash From Continuing Financing Activities	0.02	0.25	0.25	0.32	0.14	0.44	0.02	0.10	1.11
Other Financing Activities, net	0.02	0.08	0.25	0.03	0.14	0.21	0.02	0.01	1.11

This table presents Nautilus Biotechnology's assets and liabilities at the end of each period, using annual balance sheet data. All values are USD millions unless otherwise specified.

Metric	2020	2021	2022	2023	2024	2025
Period end date	12/31/2020	12/31/2021	12/31/2022	12/31/2023	12/31/2024	12/31/2025
Total Assets	85	398	350	306	243	191
Total Current Assets	78	349	187	177	133	106
Cash & Equivalents	37	186	115	19	28	12
Short-Term Investments	40	160	70	154	102	91
Prepaid Expenses	0.92	3.49	2.74	3.42	2.93	2.56
Plant, Property, & Equipment, net	1.37	2.48	3.70	4.27	4.08	3.46
Total Noncurrent Assets	5.98	47	159	124	106	82
Long-Term Investments	0.00	16	129	91	76	53
Other Noncurrent Operating Assets	5.98	30	30	34	29	29
Total Liabilities & Shareholders' Equity	85	398	350	306	243	191
Total Liabilities	6.31	35	35	40	34	34
Total Current Liabilities	3.02	5.81	6.79	9.12	7.63	7.95
Accounts Payable	0.47	1.72	1.27	1.64	0.99	0.94
Accrued Expenses	1.07	3.12	3.53	3.95	2.55	3.18
Other Current Liabilities	1.48	0.97	1.99	3.54	4.10	3.83
Total Noncurrent Liabilities	3.30	29	28	31	26	26
Other Noncurrent Operating Liabilities	3.30	29	28	31	26	26
Commitments & Contingencies	0.00	0.00	0.00	0.00	0.00	0.00
Total Equity & Noncontrolling Interests	-30	364	315	265	209	157
Total Preferred & Common Equity	-30	364	315	265	209	157
Preferred Stock	0.00	0.00	0.00	0.00	0.00	0.00
Total Common Equity	-30	364	315	265	209	157
Common Stock	0.60	444	455	468	482	489
Retained Earnings	-30	-81	-139	-202	-273	-332
Accumulated Other Comprehensive Income / (Loss)	0.00	-0.18	-1.85	-0.26	0.06	0.24

This table presents Nautilus Biotechnology's assets and liabilities at the end of each period, using quarterly balance sheet data. All values are USD millions unless otherwise specified.

Metric	Q3 2023	Q1 2024	Q2 2024	Q3 2024	Q1 2025	Q2 2025	Q1 2026
Period end date	9/30/2023	3/31/2024	6/30/2024	9/30/2024	3/31/2025	6/30/2025	3/31/2026
Total Assets	318	289	273	260	228	213	178
Total Current Assets	187	185	171	144	142	151	99
Cash & Equivalents	74	26	25	4.41	33	34	15
Short-Term Investments	109	156	143	136	106	113	81
Prepaid Expenses	3.50	3.73	3.49	3.60	2.79	2.85	2.96
Plant, Property, & Equipment, net	4.28	4.53	4.69	4.32	3.79	3.73	3.64
Total Noncurrent Assets	127	99	97	111	82	59	75
Long-Term Investments	92	66	65	81	54	32	48
Other Noncurrent Operating Assets	35	33	32	31	28	27	28
Total Liabilities & Shareholders' Equity	318	289	273	260	228	213	178
Total Liabilities	41	39	37	36	33	32	33
Total Current Liabilities	8.89	9.21	8.68	8.66	8.16	8.14	8.34
Accounts Payable	1.14	1.86	1.63	1.49	0.84	0.97	1.19
Accrued Expenses	4.29	3.68	3.24	3.22	3.07	2.94	3.31
Other Current Liabilities	3.47	3.68	3.82	3.96	4.24	4.23	3.85
Total Noncurrent Liabilities	32	30	29	28	25	24	25
Other Noncurrent Operating Liabilities	32	30	29	28	25	24	25
Commitments & Contingencies	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Total Equity & Noncontrolling Interests	277	249	235	223	194	181	144
Total Preferred & Common Equity	277	249	235	223	194	181	144
Preferred Stock	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Total Common Equity	277	249	235	223	194	181	144
Common Stock	465	471	475	478	484	486	491
Retained Earnings	-185	-221	-239	-255	-290	-305	-347
Accumulated Other Comprehensive Income / (Loss)	-2.03	-0.75	-0.55	0.73	0.19	0.08	-0.09

This table displays calculated financial ratios and metrics derived from Nautilus Biotechnology's official financial filings.

Metric	2020	2021	2022	2023	2024	2025
Period end date	12/31/2020	12/31/2021	12/31/2022	12/31/2023	12/31/2024	12/31/2025
DEI Shares Outstanding	19,186,500.00	124,166,776.00	124,723,525.00	124,945,774.00	-	126,305,122.00
DEI Adjusted Shares Outstanding	19,186,500.00	124,166,776.00	124,723,525.00	124,945,774.00	-	126,305,122.00
DEI Earnings Per Adjusted Shares Outstanding	-0.81	-0.41	-0.46	-0.51	-	-0.47
Growth Metrics	-	-	-	-	-	-
Revenue Growth	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
EBITDA Growth	0.00%	-263.06%	-28.55%	-19.55%	-6.60%	20.66%
EBIT Growth	0.00%	-221.67%	-25.86%	-19.59%	-7.00%	18.01%
NOPAT Growth	0.00%	-220.74%	-25.98%	-19.70%	-6.99%	17.97%
Net Income Growth	0.00%	-222.14%	-15.12%	-9.93%	-11.16%	16.64%
EPS Growth	0.00%	-11.11%	23.33%	-10.87%	-9.80%	16.07%
Operating Cash Flow Growth	0.00%	-180.37%	-16.73%	-12.89%	-14.38%	14.29%
Free Cash Flow Firm Growth	0.00%	0.00%	-27.16%	-20.23%	-9.13%	22.34%
Invested Capital Growth	0.00%	-24.50%	-13.01%	0.31%	88.82%	-65.95%
Revenue Q/Q Growth	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
EBITDA Q/Q Growth	0.00%	0.00%	-0.17%	-4.51%	-0.02%	0.00%
EBIT Q/Q Growth	0.00%	0.00%	0.61%	-5.19%	0.04%	0.00%
NOPAT Q/Q Growth	0.00%	0.00%	0.80%	-5.10%	0.03%	0.00%
Net Income Q/Q Growth	0.00%	0.00%	5.36%	-6.02%	-0.81%	0.00%
EPS Q/Q Growth	0.00%	0.00%	-15.00%	-6.25%	-1.82%	0.00%
Operating Cash Flow Q/Q Growth	0.00%	-17.32%	0.31%	-7.31%	-0.70%	0.00%
Free Cash Flow Firm Q/Q Growth	0.00%	0.00%	0.00%	-5.42%	-0.81%	0.00%
Invested Capital Q/Q Growth	0.00%	0.00%	-24.11%	-16.63%	10.19%	0.00%
Profitability Metrics	-	-	-	-	-	-
Gross Margin	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
EBITDA Margin	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Operating Margin	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
EBIT Margin	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Profit (Net Income) Margin	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Tax Burden Percent	99.21%	100.00%	100.00%	100.00%	100.00%	100.00%
Interest Burden Percent	100.00%	99.35%	90.88%	83.54%	86.78%	88.23%
Effective Tax Rate	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Return on Invested Capital (ROIC)	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
ROIC Less NNEP Spread (ROIC-NNEP)	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Return on Net Nonoperating Assets (RNNOA)	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Return on Equity (ROE)	-19.85%	-22.75%	-17.07%	-21.95%	-29.86%	-32.27%
Cash Return on Invested Capital (CROIC)	0.00%	-2,032.62%	-3,213.09%	-4,145.44%	-3,127.81%	-2,771.90%
Operating Return on Assets (OROA)	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Return on Assets (ROA)	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Return on Common Equity (ROCE)	7.50%	-17.18%	-17.07%	-21.95%	-29.86%	-32.27%
Return on Equity Simple (ROE_SIMPLE)	52.55%	-13.84%	-18.39%	-24.00%	-33.91%	0.00%
Net Operating Profit after Tax (NOPAT)	-11	-35	-45	-53	-57	-47
NOPAT Margin	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Net Nonoperating Expense Percent (NNEP)	-5.99%	-6.82%	-3.96%	-3.59%	-5.85%	-6.74%
Return On Investment Capital (ROIC_SIMPLE)	-	-	-	-20.09%	-27.32%	-29.81%
Cost of Revenue to Revenue	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
SG&A Expenses to Revenue	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
R&D to Revenue	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Operating Expenses to Revenue	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Earnings before Interest and Taxes (EBIT)	-16	-51	-64	-76	-82	-67
Earnings before Interest, Taxes, Depreciation and Amortization (EBITDA)	-13	-48	-61	-73	-78	-62
Valuation Ratios	-	-	-	-	-	-
Price to Book Value (P/BV)	0.00	1.77	0.71	1.41	1.01	1.57
Price to Tangible Book Value (P/TBV)	0.00	1.77	0.71	1.41	1.01	1.57
Price to Revenue (P/Rev)	0.00	0.00	0.00	0.00	0.00	0.00
Price to Earnings (P/E)	0.00	0.00	0.00	0.00	0.00	0.00
Dividend Yield	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Earnings Yield	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Enterprise Value to Invested Capital (EV/IC)	0.00	190.44	0.00	85.03	1.91	108.88
Enterprise Value to Revenue (EV/Rev)	0.00	0.00	0.00	0.00	0.00	0.00
Enterprise Value to EBITDA (EV/EBITDA)	0.00	0.00	0.00	0.00	0.00	0.00
Enterprise Value to EBIT (EV/EBIT)	0.00	0.00	0.00	0.00	0.00	0.00
Enterprise Value to NOPAT (EV/NOPAT)	0.00	0.00	0.00	0.00	0.00	0.00
Enterprise Value to Operating Cash Flow (EV/OCF)	0.00	0.00	0.00	0.00	0.00	0.00
Enterprise Value to Free Cash Flow (EV/FCFF)	0.00	0.00	0.00	0.00	0.00	0.00
Leverage & Solvency	-	-	-	-	-	-
Debt to Equity	0.00	0.00	0.00	0.00	0.00	0.00
Long-Term Debt to Equity	0.00	0.00	0.00	0.00	0.00	0.00
Financial Leverage	-0.98	-0.99	-1.00	-1.00	-0.99	-0.99
Leverage Ratio	1.08	1.09	1.10	1.13	1.16	1.19
Compound Leverage Factor	1.08	1.09	1.00	0.94	1.00	1.05
Debt to Total Capital	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Short-Term Debt to Total Capital	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Long-Term Debt to Total Capital	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Preferred Equity to Total Capital	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Noncontrolling Interests to Total Capital	137.77%	0.00%	0.00%	0.00%	0.00%	0.00%
Common Equity to Total Capital	-37.77%	100.00%	100.00%	100.00%	100.00%	100.00%
Debt to EBITDA	0.00	0.00	0.00	0.00	0.00	0.00
Net Debt to EBITDA	0.00	0.00	0.00	0.00	0.00	0.00
Long-Term Debt to EBITDA	0.00	0.00	0.00	0.00	0.00	0.00
Debt to NOPAT	0.00	0.00	0.00	0.00	0.00	0.00
Net Debt to NOPAT	0.00	0.00	0.00	0.00	0.00	0.00
Long-Term Debt to NOPAT	0.00	0.00	0.00	0.00	0.00	0.00
Altman Z-Score	0.00	11.40	3.30	4.48	1.66	1.36
Noncontrolling Interest Sharing Ratio	137.77%	24.51%	0.00%	0.00%	0.00%	0.00%
Liquidity Ratios	-	-	-	-	-	-
Current Ratio	25.73	60.09	27.57	19.39	17.40	13.33
Quick Ratio	25.43	59.49	27.16	19.01	17.02	13.00
Cash Flow Metrics	-	-	-	-	-	-
Free Cash Flow to Firm (FCFF)	0.00	-35	-44	-53	-58	-45
Operating Cash Flow to CapEx	-1,519.65%	-1,729.44%	-1,971.00%	-2,117.57%	-2,787.23%	-3,969.93%
Free Cash Flow to Firm to Interest Expense	0.00	0.00	0.00	0.00	0.00	0.00
Operating Cash Flow to Interest Expense	0.00	0.00	0.00	0.00	0.00	0.00
Operating Cash Flow Less CapEx to Interest Expense	0.00	0.00	0.00	0.00	0.00	0.00
Efficiency Ratios	-	-	-	-	-	-
Asset Turnover	0.00	0.00	0.00	0.00	0.00	0.00
Accounts Receivable Turnover	0.00	0.00	0.00	0.00	0.00	0.00
Inventory Turnover	0.00	0.00	0.00	0.00	0.00	0.00
Fixed Asset Turnover	0.00	0.00	0.00	0.00	0.00	0.00
Accounts Payable Turnover	0.00	0.00	0.00	0.00	0.00	0.00
Days Sales Outstanding (DSO)	0.00	0.00	0.00	0.00	0.00	0.00
Days Inventory Outstanding (DIO)	0.00	0.00	0.00	0.00	0.00	0.00
Days Payable Outstanding (DPO)	0.00	0.00	0.00	0.00	0.00	0.00
Cash Conversion Cycle (CCC)	0.00	0.00	0.00	0.00	0.00	0.00
Capital & Investment Metrics	-	-	-	-	-	-
Invested Capital	1.96	1.48	1.28	1.29	2.43	0.83
Invested Capital Turnover	0.00	0.00	0.00	0.00	0.00	0.00
Increase / (Decrease) in Invested Capital	0.00	-0.48	-0.19	0.00	1.14	-1.60
Enterprise Value (EV)	0.00	281	-89	110	4.65	90
Market Capitalization	0.00	643	225	374	211	246
Book Value per Share	($1.55)	$2.93	$2.53	$2.12	$1.66	$1.24
Tangible Book Value per Share	($1.55)	$2.93	$2.53	$2.12	$1.66	$1.24
Total Capital	79	364	315	265	209	157
Total Debt	0.00	0.00	0.00	0.00	0.00	0.00
Total Long-Term Debt	0.00	0.00	0.00	0.00	0.00	0.00
Net Debt	-77	-362	-314	-264	-206	-156
Capital Expenditures (CapEx)	0.92	2.27	2.32	2.44	2.12	1.28
Debt-free, Cash-free Net Working Capital (DFCFNWC)	-2.10	-2.32	-4.05	-5.70	-4.70	-5.40
Debt-free Net Working Capital (DFNWC)	75	343	180	168	125	98
Net Working Capital (NWC)	75	343	180	168	125	98
Net Nonoperating Expense (NNE)	4.60	15	13	10	14	12
Net Nonoperating Obligations (NNO)	-77	-362	-314	-264	-206	-156
Total Depreciation and Amortization (D&A)	2.63	3.03	2.53	3.05	3.55	5.05
Debt-free, Cash-free Net Working Capital to Revenue	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Debt-free Net Working Capital to Revenue	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Net Working Capital to Revenue	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Earnings Adjustments	-	-	-	-	-	-
Adjusted Basic Earnings per Share	$0.00	($0.60)	($0.46)	($0.51)	($0.56)	($0.47)
Adjusted Weighted Average Basic Shares Outstanding	0.00	84.46M	124.59M	124.92M	125.43M	126.26M
Adjusted Diluted Earnings per Share	$0.00	($0.60)	($0.46)	($0.51)	($0.56)	($0.47)
Adjusted Weighted Average Diluted Shares Outstanding	0.00	84.46M	124.59M	124.92M	125.43M	126.26M
Adjusted Basic & Diluted Earnings per Share	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00
Adjusted Weighted Average Basic & Diluted Shares Outstanding	0.00	124.43M	124.87M	125.10M	126.15M	126.56M
Normalized Net Operating Profit after Tax (NOPAT)	-11	-35	-45	-53	-57	-47
Normalized NOPAT Margin	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Pre Tax Income Margin	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Debt Service Ratios	-	-	-	-	-	-
EBIT to Interest Expense	0.00	0.00	0.00	0.00	0.00	0.00
NOPAT to Interest Expense	0.00	0.00	0.00	0.00	0.00	0.00
EBIT Less CapEx to Interest Expense	0.00	0.00	0.00	0.00	0.00	0.00
NOPAT Less CapEx to Interest Expense	0.00	0.00	0.00	0.00	0.00	0.00
Payout Ratios	-	-	-	-	-	-
Dividend Payout Ratio	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Augmented Payout Ratio	0.00%	-16.16%	0.00%	0.00%	0.00%	0.00%

This table displays calculated financial ratios and metrics derived from Nautilus Biotechnology's official financial filings.

Metric	Q3 2023	Q4 2023	Q1 2024	Q2 2024	Q3 2024	Q4 2024	Q1 2025	Q2 2025	Q1 2026
Period end date	9/30/2023	12/31/2023	3/31/2024	6/30/2024	9/30/2024	12/31/2024	3/31/2025	6/30/2025	3/31/2026
DEI Shares Outstanding	124,930,899.00	124,945,774.00	124,945,774.00	125,265,015.00	125,411,248.00	-	-	126,148,469.00	126,564,473.00
DEI Adjusted Shares Outstanding	124,930,899.00	124,945,774.00	124,945,774.00	125,265,015.00	125,411,248.00	-	-	126,148,469.00	126,564,473.00
DEI Earnings Per Adjusted Shares Outstanding	-0.13	-0.14	-0.15	-0.14	-0.13	-	-	-0.12	-0.12
Growth Metrics	-	-	-	-	-	-	-	-	-
Revenue Growth	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
EBITDA Growth	-19.20%	-19.85%	-18.26%	-20.54%	-0.06%	-0.07%	14.48%	27.88%	17.06%
EBIT Growth	-19.58%	-23.08%	-19.62%	-9.34%	-0.24%	0.16%	12.79%	17.76%	14.35%
NOPAT Growth	-20.58%	-22.68%	-19.64%	-9.32%	-0.13%	0.11%	12.79%	17.76%	14.43%
Net Income Growth	-12.91%	-26.96%	-25.16%	-13.93%	-3.58%	-3.35%	11.30%	16.53%	11.53%
EPS Growth	-18.18%	-30.00%	-25.00%	-7.69%	0.00%	-7.69%	13.33%	14.29%	7.69%
Operating Cash Flow Growth	-22.72%	-33.95%	-29.88%	-14.08%	-11.71%	-2.94%	14.32%	13.63%	6.01%
Free Cash Flow Firm Growth	-48.53%	-24.81%	-11.24%	-2.82%	-6.26%	-8.04%	14.93%	19.99%	17.23%
Invested Capital Growth	-8.69%	0.31%	6.26%	-19.52%	42.85%	88.82%	-12.65%	-33.12%	-35.02%
Revenue Q/Q Growth	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
EBITDA Q/Q Growth	0.50%	-4.75%	-8.81%	-6.29%	8.45%	-4.77%	7.02%	10.37%	0.00%
EBIT Q/Q Growth	-0.24%	-5.15%	-7.73%	3.70%	8.11%	-4.73%	5.90%	9.19%	0.00%
NOPAT Q/Q Growth	-0.31%	-4.85%	-8.03%	3.79%	8.12%	-4.61%	5.69%	9.27%	0.00%
Net Income Q/Q Growth	-0.44%	-7.22%	-10.02%	3.84%	8.68%	-6.98%	5.58%	9.51%	0.00%
EPS Q/Q Growth	0.00%	0.00%	-15.38%	6.67%	7.14%	-7.69%	7.14%	7.69%	0.00%
Operating Cash Flow Q/Q Growth	13.37%	-18.42%	-17.02%	4.97%	15.16%	-9.12%	2.60%	4.21%	0.00%
Free Cash Flow Firm Q/Q Growth	2.86%	-6.05%	-8.77%	8.24%	-0.39%	-7.83%	14.35%	13.70%	0.00%
Invested Capital Q/Q Growth	-47.54%	-16.63%	42.39%	29.23%	-6.88%	10.19%	-34.13%	-1.06%	0.00%
Profitability Metrics	-	-	-	-	-	-	-	-	-
Gross Margin	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
EBITDA Margin	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Operating Margin	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
EBIT Margin	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Profit (Net Income) Margin	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Tax Burden Percent	100.00%	100.00%	100.00%	100.00%	100.00%	100.00%	100.00%	100.00%	100.00%
Interest Burden Percent	83.24%	84.88%	86.68%	86.55%	86.01%	87.86%	88.16%	87.85%	91.07%
Effective Tax Rate	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Return on Invested Capital (ROIC)	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
ROIC Less NNEP Spread (ROIC-NNEP)	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Return on Net Nonoperating Assets (RNNOA)	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Return on Equity (ROE)	-19.93%	-21.95%	-24.38%	-26.53%	-28.04%	-29.86%	-30.93%	-31.55%	-33.69%
Cash Return on Invested Capital (CROIC)	-3,124.59%	-4,145.44%	-3,140.30%	-2,124.38%	-3,076.22%	-3,127.81%	-3,193.66%	-2,615.91%	-3,353.83%
Operating Return on Assets (OROA)	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Return on Assets (ROA)	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Return on Common Equity (ROCE)	-19.93%	-21.95%	-24.38%	-26.53%	-28.04%	-29.86%	-30.93%	-31.55%	-33.69%
Return on Equity Simple (ROE_SIMPLE)	-21.66%	0.00%	-27.03%	0.00%	-31.42%	0.00%	-35.31%	0.00%	0.00%
Net Operating Profit after Tax (NOPAT)	-13	-14	-15	-15	-13	-14	-13	-12	-11
NOPAT Margin	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Net Nonoperating Expense Percent (NNEP)	-0.84%	-1.05%	-1.31%	-1.33%	-1.24%	-1.53%	-1.55%	-1.49%	-2.03%
Return On Investment Capital (ROIC_SIMPLE)	-	-5.28%	-6.06%	-6.19%	-	-6.70%	-6.78%	-6.61%	-7.82%
Cost of Revenue to Revenue	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
SG&A Expenses to Revenue	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
R&D to Revenue	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Operating Expenses to Revenue	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Earnings before Interest and Taxes (EBIT)	-19	-20	-22	-21	-19	-20	-19	-17	-16
Earnings before Interest, Taxes, Depreciation and Amortization (EBITDA)	-18	-19	-21	-22	-18	-19	-18	-16	-15
Valuation Ratios	-	-	-	-	-	-	-	-	-
Price to Book Value (P/BV)	1.42	1.41	1.47	1.25	1.60	1.01	0.56	0.51	3.40
Price to Tangible Book Value (P/TBV)	1.42	1.41	1.47	1.25	1.60	1.01	0.56	0.51	3.40
Price to Revenue (P/Rev)	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Price to Earnings (P/E)	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Dividend Yield	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Earnings Yield	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Enterprise Value to Invested Capital (EV/IC)	77.06	85.03	65.26	25.41	61.71	1.91	0.00	0.00	334.00
Enterprise Value to Revenue (EV/Rev)	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Enterprise Value to EBITDA (EV/EBITDA)	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Enterprise Value to EBIT (EV/EBIT)	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Enterprise Value to NOPAT (EV/NOPAT)	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Enterprise Value to Operating Cash Flow (EV/OCF)	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Enterprise Value to Free Cash Flow (EV/FCFF)	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Leverage & Solvency	-	-	-	-	-	-	-	-	-
Debt to Equity	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Long-Term Debt to Equity	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Financial Leverage	-0.99	-1.00	-0.99	-0.99	-0.99	-0.99	-0.99	-0.99	-0.99
Leverage Ratio	1.12	1.13	1.15	1.15	1.15	1.16	1.16	1.17	1.20
Compound Leverage Factor	0.94	0.96	0.99	1.00	0.99	1.02	1.03	1.03	1.09
Debt to Total Capital	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Short-Term Debt to Total Capital	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Long-Term Debt to Total Capital	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Preferred Equity to Total Capital	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Noncontrolling Interests to Total Capital	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Common Equity to Total Capital	100.00%	100.00%	100.00%	100.00%	100.00%	100.00%	100.00%	100.00%	100.00%
Debt to EBITDA	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Net Debt to EBITDA	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Long-Term Debt to EBITDA	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Debt to NOPAT	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Net Debt to NOPAT	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Long-Term Debt to NOPAT	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Altman Z-Score	5.43	5.09	5.04	3.93	4.92	2.49	0.61	0.25	6.41
Noncontrolling Interest Sharing Ratio	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Liquidity Ratios	-	-	-	-	-	-	-	-	-
Current Ratio	21.00	19.39	20.09	19.69	16.65	17.40	17.36	18.52	11.85
Quick Ratio	20.61	19.01	19.69	19.29	16.23	17.02	17.02	18.17	11.49
Cash Flow Metrics	-	-	-	-	-	-	-	-	-
Free Cash Flow to Firm (FCFF)	-13	-14	-15	-14	-14	-15	-13	-11	-11
Operating Cash Flow to CapEx	-1,343.02%	-3,365.62%	-2,514.06%	-3,018.95%	-1,849.51%	-5,633.46%	-6,363.93%	-3,371.21%	-2,568.63%
Free Cash Flow to Firm to Interest Expense	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Operating Cash Flow to Interest Expense	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Operating Cash Flow Less CapEx to Interest Expense	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Efficiency Ratios	-	-	-	-	-	-	-	-	-
Asset Turnover	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Accounts Receivable Turnover	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Inventory Turnover	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Fixed Asset Turnover	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Accounts Payable Turnover	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Days Sales Outstanding (DSO)	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Days Inventory Outstanding (DIO)	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Days Payable Outstanding (DPO)	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Cash Conversion Cycle (CCC)	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Capital & Investment Metrics	-	-	-	-	-	-	-	-	-
Invested Capital	1.55	1.29	1.83	2.37	2.21	2.43	1.60	1.59	1.04
Invested Capital Turnover	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Increase / (Decrease) in Invested Capital	-0.15	0.00	0.11	-0.58	0.66	1.14	-0.23	-0.79	-0.56
Enterprise Value (EV)	119	110	120	60	136	4.65	-84	-88	348
Market Capitalization	395	374	367	293	357	211	109	91	491
Book Value per Share	$2.22	$2.12	$1.99	$1.88	$1.78	$1.66	$1.54	$1.44	$1.14
Tangible Book Value per Share	$2.22	$2.12	$1.99	$1.88	$1.78	$1.66	$1.54	$1.44	$1.14
Total Capital	277	265	249	235	223	209	194	181	144
Total Debt	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Total Long-Term Debt	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Net Debt	-276	-264	-248	-233	-221	-206	-193	-180	-143
Capital Expenditures (CapEx)	0.87	0.41	0.65	0.51	0.71	0.25	0.22	0.40	0.51
Debt-free, Cash-free Net Working Capital (DFCFNWC)	-5.40	-5.70	-5.48	-5.19	-5.07	-4.70	-5.37	-5.29	-5.38
Debt-free Net Working Capital (DFNWC)	178	168	176	162	136	125	133	143	90
Net Working Capital (NWC)	178	168	176	162	136	125	133	143	90
Net Nonoperating Expense (NNE)	2.53	3.02	3.61	3.46	3.08	3.61	3.42	3.07	3.41
Net Nonoperating Obligations (NNO)	-276	-264	-248	-233	-221	-206	-193	-180	-143
Total Depreciation and Amortization (D&A)	0.86	0.97	0.84	-1.27	0.89	0.93	1.08	1.19	1.41
Debt-free, Cash-free Net Working Capital to Revenue	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Debt-free Net Working Capital to Revenue	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Net Working Capital to Revenue	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Earnings Adjustments	-	-	-	-	-	-	-	-	-
Adjusted Basic Earnings per Share	($0.13)	($0.13)	($0.15)	($0.14)	($0.13)	($0.14)	($0.13)	($0.12)	($0.12)
Adjusted Weighted Average Basic Shares Outstanding	124.93M	124.92M	125.14M	125.32M	125.45M	125.43M	126.14M	126.20M	126.63M
Adjusted Diluted Earnings per Share	($0.13)	($0.13)	($0.15)	($0.14)	($0.13)	($0.14)	($0.13)	($0.12)	($0.12)
Adjusted Weighted Average Diluted Shares Outstanding	124.93M	124.92M	125.14M	125.32M	125.45M	125.43M	126.14M	126.20M	126.63M
Adjusted Basic & Diluted Earnings per Share	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00
Adjusted Weighted Average Basic & Diluted Shares Outstanding	124.95M	125.10M	125.27M	125.41M	125.56M	126.15M	126.15M	126.31M	127.08M
Normalized Net Operating Profit after Tax (NOPAT)	-13	-14	-15	-15	-13	-14	-13	-12	-11
Normalized NOPAT Margin	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Pre Tax Income Margin	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Debt Service Ratios	-	-	-	-	-	-	-	-	-
EBIT to Interest Expense	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
NOPAT to Interest Expense	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
EBIT Less CapEx to Interest Expense	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
NOPAT Less CapEx to Interest Expense	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Payout Ratios	-	-	-	-	-	-	-	-	-
Dividend Payout Ratio	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Augmented Payout Ratio	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%

Financials Breakdown Chart

Nautilus Biotechnology Financials - Frequently Asked Questions

According to the most recent income statement we have on file, Nautilus Biotechnology's financial year ends in December. Their financial year 2025 ended on December 31, 2025.

Nautilus Biotechnology's net income appears to be on an upward trend, with a most recent value of -$59.00 million in 2025, rising from -$15.62 million in 2020. The previous period was -$70.78 million in 2024. See Nautilus Biotechnology's forecast for analyst expectations on what's next for the company.

Nautilus Biotechnology's total operating income in 2025 was -$66.84 million, based on the following breakdown:

Total Gross Profit: $0.00
Total Operating Expenses: $66.84 million

Over the last 5 years, Nautilus Biotechnology's total revenue changed from $0.00 in 2020 to $0.00 in 2025, a change of 0.0%.

Nautilus Biotechnology's total liabilities were at $34.14 million at the end of 2025, a 0.4% increase from 2024, and a 440.7% increase since 2020.

In the past 5 years, Nautilus Biotechnology's cash and equivalents has ranged from $12.39 million in 2025 to $185.62 million in 2021, and is currently $12.39 million as of their latest financial filing in 2025.

Over the last 5 years, Nautilus Biotechnology's book value per share changed from -1.55 in 2020 to 1.24 in 2025, a change of -180.3%.

Related Companies

Financial statements for NASDAQ:NAUT last updated on 7/2/2026 by MarketBeat.com Staff. New filings and market data are monitored continuously.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Nautilus Biotechnology (NAUT) Financials

Financials Breakdown Chart

Nautilus Biotechnology Financials - Frequently Asked Questions

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Nautilus Biotechnology (NAUT) Financials

Annual Income Statements for Nautilus Biotechnology

Quarterly Income Statements for Nautilus Biotechnology

Annual Cash Flow Statements for Nautilus Biotechnology

Quarterly Cash Flow Statements for Nautilus Biotechnology

Annual Balance Sheets for Nautilus Biotechnology

Quarterly Balance Sheets for Nautilus Biotechnology

Annual Metrics And Ratios for Nautilus Biotechnology

Quarterly Metrics And Ratios for Nautilus Biotechnology

Financials Breakdown Chart

Nautilus Biotechnology Financials - Frequently Asked Questions

When does Nautilus Biotechnology's fiscal year end?

How has Nautilus Biotechnology's net income changed over the last 5 years?

What is Nautilus Biotechnology's operating income?

How has Nautilus Biotechnology's revenue changed over the last 5 years?

How much debt does Nautilus Biotechnology have?

How much cash does Nautilus Biotechnology have?

How has Nautilus Biotechnology's book value per share changed over the last 5 years?

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools